---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045860"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:23:30.081092+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience Q3 2024: cash $11.2M; grants up to $10.7M and $10M; pipeline advancing

## Summary
- Cash and equivalents $11.2M at Sept 30, 2024; R&D expenses fell 60% YoY to $2.7M; G&A $2.0M.
- Foundation grant of up to ~$10.7M for novel non-hormonal contraceptive and to add Ovaprene Phase 3 sites.
- ARPA-H award of $10M for DARE-HPV IND-enabling activities; NICHD grant of $2M for DARE-PTB1.
- Ovaprene Phase 3 enrolling at 10 US sites; target ~125 women completing 6 mo by Q2 2025.
- Sildenafil Cream Phase 3 discussions with FDA ongoing; each Phase 3 study est. ~$15M direct costs.

## SEC filing metadata
- accession: 0001493152-24-045860
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315224045860/0001493152-24-045860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315224045860/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045860
- JSON: https://secwatch.observer/filing/0001493152-24-045860.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.